Novartis Content With CAR-T Manufacturing Ahead Of Crucial FDA Panel
Executive Summary
As crunch time approaches with its eagerly-anticipated CAR-T advisory meeting with FDA advisors on Wednesday, Novartis has been looking to allay fears about the manufacturing of CTL019.
You may also be interested in...
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin
The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.
Novo Pumps Up Heart Failure Prospects With Cardior Purchase
The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.